MedAvail Holdings stock (US58406B1035): reverse stock split and restructuring keep investors on edge

MedAvail Holdings is executing a 1-for-100 reverse stock split and restructuring its pharmacy technology business after selling core assets, leaving the micro-cap stock volatile and speculative for investors watching the US healthcare and retail pharmacy space.

MedAvail Holdings is in the middle of a far?reaching restructuring after selling key assets, combining a drastic 1?for?100 reverse stock split with a pivot of its pharmacy technology platform, according to company disclosures published in early 2025 and late 2024 on its investor relations site and regulatory filings (MedAvail Investor Relations as of 03/20/2025; SEC filings as of 12/20/2024). The thinly traded micro?cap stock has been highly volatile around these corporate actions, a dynamic that is particularly relevant for US investors focused on small healthcare and retail pharmacy technology names on US exchanges.

As of: 08.06.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: MedAvail Holdings
• Sector/industry: Healthcare technology / pharmacy automation
• Headquarters/country: United States
• Core markets: Retail pharmacy operators and outpatient clinical settings in North America
• Key revenue drivers: Pharmacy kiosk technology, software services and support fees
• Home exchange/listing venue: Nasdaq (ticker if verified)
• Trading currency: US dollar (USD)

MedAvail Holdings: core business model

MedAvail Holdings historically focused on developing and operating self?service pharmacy kiosks and technology platforms designed to dispense prescription medications in clinics and retail locations, as described in its past annual and quarterly reports filed with the SEC in 2023 and 2024 (SEC Form 10?K as of 03/29/2024). The company’s offering combined a physical dispensing machine, remote pharmacist support and integrated software intended to increase medication access while lowering the operating costs of full?service pharmacies for healthcare providers.

In that model, MedAvail’s revenue mix included equipment sales or placements of its pharmacy kiosks, recurring software and network fees, and service revenue from operating and maintaining the machines, according to the 2023 annual report published in March 2024 (SEC Form 10?K as of 03/29/2024). The company worked with clinic operators and retail chains that wanted to extend pharmacy access into smaller or lower?traffic locations, a segment that sits at the intersection of healthcare delivery and retail convenience.

MedAvail’s technology platform typically integrated with electronic health record and prescribing systems, aiming to streamline the process from prescription to medication pick?up, based on product descriptions and investor presentations from 2023 and 2024 (MedAvail Investor Relations as of 05/15/2024). For US investors tracking healthcare IT and retail pharmacy innovation, MedAvail represented a niche play on automation and point?of?care dispensing rather than a traditional drug manufacturer or large national pharmacy operator.

Main revenue and product drivers for MedAvail Holdings

Before the latest restructuring, MedAvail’s primary revenue drivers were installations and utilization of its MedAvail?branded kiosks in partner locations, which generated both upfront and recurring revenue streams, according to the 2023 Form 10?K filed in March 2024 (SEC Form 10?K as of 03/29/2024). Higher prescription volumes flowing through each machine typically improved the economics of those deployments, making utilization a key driver for both MedAvail and its customers.

Software services formed another important piece of the revenue mix, as the company licensed its platform for managing prescriptions, inventory and remote verification to healthcare partners, according to MedAvail’s filings and investor communications in 2023 and 2024 (MedAvail Investor Relations as of 05/15/2024). Those recurring fees were central to the business model because they could, in principle, provide more predictable cash flow than hardware sales alone, a characteristic often valued by investors analyzing small?cap healthcare technology companies.

In addition, MedAvail historically offered implementation, maintenance and support services that provided incremental revenue and aimed to ensure that deployed kiosks complied with pharmacy regulations and operated reliably in clinical environments (SEC Form 10?K as of 03/29/2024). For US investors comparing MedAvail with larger equipment and software vendors, this services component underscored the operational intensity of the model and the company’s reliance on long?term customer relationships.

Conclusion

MedAvail Holdings illustrates both the potential and the risks of small US healthcare technology stocks focused on pharmacy automation, particularly after a major restructuring and reverse stock split documented in its recent filings and press releases (MedAvail Investor Relations as of 03/20/2025). For US investors, the company offers exposure to a niche segment of the retail pharmacy and clinic ecosystem, but its micro?cap profile, strategic shifts and history of operating losses underscore the importance of closely following official updates on strategy, funding and customer traction. The stock’s speculative nature and sharp price swings mean market participants often pay close attention to MedAvail’s regulatory filings, earnings releases and corporate actions when assessing its future prospects and role within a diversified healthcare or technology portfolio.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.